SAB Biotherapeutics (SABS) Gains from Investment Securities (2021 - 2026)
SAB Biotherapeutics (SABS) posted Gains from Investment Securities of $482474.0 for Q1 2026, down 85.17% on a QoQ basis from $3.3 million in Q4 2025, and up 109.58% year-over-year from $230208.9 in Q1 2025.
SAB Biotherapeutics (SABS) Gains from Investment Securities (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at $482474.0 for Q1 2026.
- Quarterly Gains from Investment Securities rose 109.58% year-over-year to $482474.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.2 million (down 1055.68% YoY) and the FY2025 annual result came in at -$62.8 million, down 1065.35% from the prior year.
- Gains from Investment Securities was $482474.0 for Q1 2026 at SAB Biotherapeutics, down from $3.3 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $4.7 million in Q4 2023 and bottomed at -$61.6 million in Q3 2025.
- A 5-year average of -$4.3 million and a median of -$82586.0 in 2023 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 13020.42% — and 2025, when it plunged 998099.77%.
- SAB Biotherapeutics' Gains from Investment Securities stood at -$36586.0 in 2022, then jumped by 13020.42% to $4.7 million in 2023, then tumbled by 51.21% to $2.3 million in 2024, then soared by 41.06% to $3.3 million in 2025, then slumped by 85.17% to $482474.0 in 2026.
- Business Quant data shows SABS's Gains from Investment Securities at $482474.0 in Q1 2026, $3.3 million in Q4 2025, and -$61.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | SAB Biotherapeutics | 185.85 Mn | 185.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 482,474.00 |
| Mar 31, 2026 | 482,474.00 |
| Dec 31, 2025 | 3.25 Mn |
| Dec 31, 2025 | 3.25 Mn |
| Sep 30, 2025 | -61.60 Mn |
| Sep 30, 2025 | -61.60 Mn |
| Jun 30, 2025 | 627,056.00 |
| Jun 30, 2025 | 627,056.00 |
| Mar 31, 2025 | -5.04 Mn |
| Mar 31, 2025 | -5.04 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Sep 30, 2024 | -6,171.00 |
| Sep 30, 2024 | -6,171.00 |
| Jun 30, 2024 | -2.22 Mn |
| Jun 30, 2024 | -2.22 Mn |
| Mar 31, 2024 | -5.47 Mn |
| Mar 31, 2024 | -5.47 Mn |
| Dec 31, 2023 | 4.73 Mn |
| Dec 31, 2023 | 4.73 Mn |